Summary Thirty-five patients with advanced malignant disease have been treated as outpatients with increasing doses (0.1 -00 mcg) of interleukin 2 (IL2) by once daily self-administered subcutaneous (s.c.) injection, 5 days weekly for 8 weeks followed by a 4 week observation period. Systemic side effects were not experienced by patients at the 3 lower doses. Three patients required dose reduciton from 100 mcg daily because of intolerance (fever, rash, lethargy, nausea and vomiting) and one patient was discontinued because of dyspnoea. We observed immunological effects at the 100 mcg dose (but not at the lower doses). These consisted of (a) a modest sustained lymphocytosis, (b) eosinophilia in six (out of nine) patients and (c) a significant rise in IL2-stimulated peripheral blood lymphocyte activated killer (LAK) cell activity in six (out of nine) patients to a mean of 2.0 times pretreatment levels (P<0.01). Two (out of nine) patients with renal cell carcinoma treated with 100 mcg daily had partial responses of duration 4 and 9 months respectively and a further three had disease stabilisation for at least 3 months. Low dose long-term s.c. IL2 is clinically and immunologically active, and in comparison to other IL2 regimens it has minor toxicity and is easy to administer. These characteristics make low dose s.c. IL2 suitable for study in the adjuvant setting.
Recombinant interleukin 2 (IL2) administered either alone or in combination with autologous, in vitro generated lymphocyte activated killer (LAK) cells shows considerable promise in the treatment of a number of types of advanced cancer such as malignant melanoma and renal cell carcinoma which respond poorly to conventional therapy (Rosenberg et al., 1987; West et al., 1987; Fisher et al., 1988) . IL2 therapy administered by intravenous (i.v.) bolus or infusion has severe toxicity at high doses and LAK cell infusion is complex and costly. The optimal dosage and scheduling of IL2
has not yet been defined, nor has it been established that the co-infusion of LAK cells is necessary to maximise the therapeutic effects of IL2. IL2 toxicity is dose related (Rosenberg et al., 1987; West et al., 1987) (Allison et al., 1989; Goldstein et al., 1989; Oliver et al., 1989) , raising the possibility that prolonged treatment with low dose IL2 may prove to be a clinically effective and non-toxic alternative to intensive regimes. Longterm i.v. infusion is cumbersome and although patients treated with 'intermediate' doses of IL2 have not required intensive care unit support, the toxicity remains substantial. These factors limit the duration of treatment.
We report the effects of low dose IL2 treatment of patients with advanced cancer for prolonged periods which for ease and simplicity of administration in an outpatient setting was given by once daily self-administered subcutaneous (s.c.) injection. (Gillis et al., 1978; Gearing & Thorpe, 1988 (Miller et al., 1981) .
Patients and methods

Patients
LAK cell generation and measurement of cytotoxicity LAK cell activity was measured using the chromium release cytotoxicity assay described previously (Malkovsky et al., 1987) . In brief, peripheral blood mononuclear cells (PBMC) were isolated from heparinized blood by lymphoprep (Nycomed) density gradient centrifugation and suspended in tissue culture medium containing 5% human serum and 500 units ml-' recombinant IL2 (Glaxo). The cells were cultured for 72 h in a humidified atmosphere of 5% CO2 in air at 37°C prior to the addition of target cells. The T-24 cells (human urinary bladder carcinoma) (Malkovsky et al., 1987) All 18 patients treated with 100 mcg daily (including both patients previously treated with 10 mcg daily), nine of whom had renal cell carcinoma, four of whom had melanoma and two with colorectal cancer, had assessable disease. Two patients with renal cell carcinoma, treated with 100 mcg daily IL2 throughout, had partial responses. One responding patient, who received three courses of IL2, had regression of unresectable locally recurrent disease with a response duration of 9 months. The other patient had regression of lymph node metastases for 4 months. The times to response were 5 and 2 months respectively. Four patients with renal cell carcnoma, who completed one, two, two and three courses of IL2, respectively, had stable disease for at least 3 months and a further two patients with melanoma also had disease stabilisation. The remaining patients had disease progression during therapy with the exception of the patient who was withdrawn because of side effects.
Side effects at 100 mcg daily Subcutaneous IL2 treatment was well tolerated by the majority of patients. Mild erythema and occasionally pruritus occurred at the injection site in all patients; the reaction usually developed after approximately 12 h and lasted for up to 60 h. Systemic side effects which were mostly very mild are summarised in Table III . Fever, shivers and headache were relatively common. The onset of symptoms was usually between 4 and 8 h after injection and in the majority of cases lasted for less than 3 h. In five patients symptoms occurred predominantly on Mondays. Fevers and shivers were controllable with paracetamol in 7 of the 11 cases. Three of the patients with fevers (including one requiring dose reduction) were treated with concomitant non-steroidal anti-inflammatory drugs.
Four patients were intolerant of the 100 mcg daily dose. One patient, who had compromised respiratory function due to a lung tumour prior to treatment, was withdrawn because of grade 3 dyspnoea after 2+ weeks therapy, although there was no evidence of pulmonary oedema in this case. His symptoms subsequently improved with steroid and bronchodilator therapy. The remaining three patients whose side effects included fever (in two), generalised erythema, headache, lethargy and nausea and vomiting had dose reductions. Side effects resolved in one patient at 50 mcg daily; the remaining two required a further dose reduction to 10 mcg daily.
With the possible exception of the patient described above, oedema, clinically apparent hypotension and other symptoms attributable to the capillary leak syndrome (Rosenstein et al., 1986) did not occur.
No changes in electrolyte levels or serum urea and creatinine were recorded during treatment. Reversible rises in alkaline phosphatase and hepatic transaminase levels to up to 3 x baseline levels occurred in four patients during the first 2 weeks of treatment. (Figure 1 ). Marked eosinophila (1-5.5 x 109 1') developed during treatment in six patients.
IL2-stimulated peripheral blood LAK cell activity before and during IL2 treatment for nine patients is shown in Table  IV . In six patients, the mean on-treatment LAK cell activity was significantly greater than the pre-treatment value (t-test). In these six patients, LAK cell activity rose to its maximum level between 2 and 3 weeks from the start of treatment. The overall mean LAK cell activity during IL2 treatment was 2. fold greater than the pretreatment mean. Although LAK activity is expressed as lytic units/l blood, the rise in values during treatment was not simply the consequence of the lymphocytosis since the rise is also apparent when lytic units are normalised to effector cell numbers (data not shown).
LAK cell activity was measured in three patients 4 weeks after discontinuation of IL2 therapy. (Sondel et al., 1988; Allison et al., 1989; Oliver et al., 1989; Urba et al., 1990 (Sondel et al., 1988) , which probably reflects the differences in dosing. The minor suppression of lymphocyte count during treatment and the development of a sustained lymphocytosis which we observed rather than the usual pattern of marked on-treatment suppression to below baseline followed by rebound (Sondel et al., 1988) is also likely to be related to IL2 dosing (Creekmore et al., 1989) . IL2 has recently been shown to be immunologically active when given by the s.c. (Atzpodien et al., 1990 ) and i.m. (Urba et al., 1990) routes.
No clear correlation has been established between the extent of the haemotological and immunological changes induced by IL2 and clinical response (Boldt et al., 1988) . However, there are no reports in humans that suggest that IL2 has clinical activity at doses at which no immunological effect can be detected. We have shown that 100 mcg of s.c. IL2 daily is clinically active (in renal cell carcinoma). The number of patients we have treated is too small to allow reliable comparisons to be made between our response data and those reported elsewhere. However our results are similar to the previously reported response rates of 16-33% in renal cell carcinoma treated with more toxic IL2 regimens and with LAK cell infusion (Rosenberg et al., 1987; Fisher et al., 1988; Marumo et al., 1989) . Our results therefore support the hypothesis that prolonged low dose therapy may be as efficacious clinically as short courses of high dose therapy.
We are not able to exclude clinical activity of doses of 10 mcg daily or less because of the relatively small number of patients treated and because a lower proportion of patients treated at these doses had tumours of types which are likely to respond to IL2. Nevertheless our data do not suggest that IL2 at these doses is likely to be clinically useful as a single agent.
The simplicity of low dose self-administered s.c. IL2 makes it very attractive in comparison to other methods of IL2 treatment. IL2 treatment may prove to be more effective in early than in advanced disease and this form of therapy would be ideally suited for study as a possible adjuvant in the treatment of appropriate solid and haematological malignancies, where self-administered outpatient therapy over long periods would be mandatory. Further studies of low dose s.c. IL2 and formal comparison with infusional regimes involving LAK cell adminstration are now required.
